Deutsche Bank analysts upgraded Eli Lilly's stock to a buy rating after a strong quarterly report. Despite a dip due to $5 billion bond sales news, the company's shares rose by nearly 15%, reaching above $904. The acquisition of Morphic and promising drug developments influenced the upgrade.